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ABSTRACT
A total of 28 treatment-naı¨ve patients with stage II or III multiple myeloma (MM) were treated with the com-
bination of clarithromycin, lenalidomide, and dexamethasone (BiRD). Stem cells were collected following gran-
ulocyte-colony stimulating factor (G-CSF) or cyclophosphamide (Cy) plus G-CSF mobilization at maximum
response. Sufficient stem cells for 2 autologous stem cell transplants were collected from all patients mobilized
with Cy plus G-CSF, versus 33% mobilized with G-CSF alone (P\ .0001). The duration of prior lenalidomide
therapy did not correlate with success of stem cell harvests (P 5 .91). In conclusion, Cy can be added to G-CSF
for stem cell mobilization to successfully overcome the suppressive effect of prior treatment with lenalidomide.
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Treatment options for patients with multiple mye-
loma (MM) have evolved with the introduction of pow-
erful new therapeutic agents. Although there has been
a recent trend to delay autologous stem cell transplanta-
tion (ASCT) until relapse, because of high response
rates obtainedwith new regimens [1], high-dose chemo-
therapy followedbyASCT,which is associatedwith im-
proved survival, remains the goal for most patients with
MM [2]. The selection of induction therapy, therefore,
must take into consideration the potential impact on the
ability to collect enough stem cells for future transplan-
tation. In addition, the goal for the absolute number of
stem cells to be collected has increased because of stud-
ies reporting a survival benefit with tandem ASCT, as
well as the potential use of high-dose chemotherapy
with stem cell rescue as salvage therapy [1,3-5].Lenalidomide (Revlimid;Celgene,NJ), anoral im-
munomodulatory (IMiD) drug, in combination with
dexamethasone, has demonstrated impressive clinical
activity in patients with both relapsed or refractory
[6,7] andnewly diagnosedMM[8].Three recent studies
reported decreased stem cell yields when granulocyte-
colony stimulating factor (G-CSF) was used for stem
cell mobilization following lenalidomide induction
therapy in patients with MM [1,9,10]. In 1 study,
decreased stem cell yield correlated with longer dura-
tion of lenalidomide therapy, and the authors recom-
mended collecting stem cells within 6 months of
initiating lenalidomide-based therapy to minimize the
risk of mobilization failures [1]. Paripati et al. [10] also
showed a trend toward increasing difficulty of stem
cell collection with longer duration of lenalidomide-
based induction therapy for MM, notably with795
796 T. Mark et al.a 100% failure rate for those patients who had received
.10 cycles. These results were not corroborated in
a third study, however [9].
In an effort to clarify the above issues, we examined
if the addition of cyclophosphamide (Cy) to G-CSF as
a mobilization regimen would facilitate the collection
of adequate stem cells for at least 2 ASCTs in
patients who had induction therapy with the BiRD
(Biaxin [clarithromycin]/Revlimid [lenalidomide]/
dexamethasone) regimen.
MATERIALS AND METHODS
Patients with stage II and III MM were treated as
part of a phase II study of the combination of clarithro-
mycin, lenalidomide, and dexamethasone (BiRD) ther-
apy, as previously published [8]. All patients received
lenalidomide and dexamethasone in 28-day cycles.
Dexamethasone 40 mg was given orally once weekly.
Lenalidomide 25 mg/day was given orally on days
1-21 of each 28-day cycle. Concurrent medications
included: clarithromycin 500 mg given orally twice
daily; aspirin 81 mg/day for deep-vein thrombosis pro-
phylaxis; omeprazole 20 mg/day for gastrointestinal
prophylaxis; and trimethoprim or sulfamethoxazole
1 double-strength tablet twice daily for Pneumocystis
carinii pneumonia prophylaxis, 3 times a week. Patients
were advised to undergo stem cell collection after
achieving a maximum disease response or disease pla-
teau, and all patientsmust have achieved at least a partial
response (PR) according to the international uniform
response criteria for MM [11]. BiRD therapy was with-
held for a minimum of 14 days prior to stem cell mobi-
lization. In this nonrandomized study, 28 patients
underwent anattemptat stemcellmobilizationandcollec-
tion. Stem cell mobilization was performed either with
G-CSF alone at a dose of 10mg/kg/day for 5-10 consec-
utive days until 10 106/kgCD341 stemcells had been
collected, or with G-CSF plus Cy, 3 g/m2 once only,
a day prior to the initiation of G-CSF as described
above. Collection success was defined by the collection
of at least 4  106/kg CD341 stem cells, which would
be the minimum number of CD341 cells to support 2
ASCT. Patients who wished to continue BiRD therapy
elected to mobilize with G-CSF alone, and those who
chose to proceed toASCT immediately aftermaximum
response received Cy plus G-CSF. In total, G-CSF
alone was given to 9 patients, and 19 patients received
Cy plus G-CSF. One patient who failed to collect an
adequate number of stem cells with G-CSF alone
requested remobilization with Cy plus G-CSF.
The number of CD341 stem cells collected, the abil-
ity tocollect sufficient stemcells for2ASCTs,and the im-
pact of duration of BiRD therapy on stem cell collection
was compared betweenmobilization regimens. The rela-
tive lenalidomide dose intensity for each patient was cal-
culated as the ratio of the dose of lenalidomide received(accounting for dose reductions) to the intending dose
of lenalidomide in theBiRDregimen.The total lenalido-
mide dose delivery was calculated as the relative lenalido-
mide dose intensity multiplied by the number of BiRD
cycles prior to stem cell collection. For example, a patient
whohadnot had anydose reduction in lenalidomide after
7 cycles of BiRD would have a total lenalidomide dose
delivery of 7. Mann-Whitney U-tests and Fisher’s exact
tests were used to calculate P values, as appropriate.
RESULTS
There were no differences in the baseline charac-
teristics of patients who were treated either with
G-CSF alone (9 patients) or Cy plus G-CSF in
combination (20 patients) (Table 1).
Significantlymore CD341 cells were collected with
Cy plus G-CSF (median 14.2  106/kg) than with
G-CSF alone (median 3.1  106/kg; P\ .0001) (Table
2 and Figure 1). All patients who received Cy plus
G-CSF for stem cell mobilization obtained a sufficient
amount of CD341 cells for 2 ASCTs, compared with
only 33%of patients who attempted stem cellmobiliza-
tion with G-CSF alone (P\ .0001). The 3 patients in
theG-CSFgroupwhohad successful collectionshad re-
ceived\6 cycles of BiRD. The extent of BiRD therapy
prior to stem cell mobilization ranged from 2-27 cycles
in both groups. The number of cycles of BiRD was not
significantly associated with the success of stem cell
harvests (median 7 cycles [range: 4-23] for unsuccessful
harvests versus 7 cycles [range: 2-27] for successful
Table 1. Baseline Characteristics of Patients with Multiple Myeloma
Treated with BiRD (Biaxin [Clarithromycin]/Revlimid
[Lenalidomide]/Dexamethasone) Regimen
Characteristic
G-CSF
(n 5 9)
Cy plus G-CSF
(n 5 20)
Male sex, n (%) 6 (67) 11 (55)
Age ± SD, years 62.3 ± 9.7 56.3 ± 11.7
Durie-Salmon stage, n (%)
IIA 3 (33) 6 (30)
IIB 0 0
IIIA 5 (56) 12 (60)
IIIB 1 (11) 2 (10)
International Staging System stage, n (%)
I 5 (56) 11 (55)
II 2 (22) 6 (30)
III 2 (22) 3 (15)
Median number of BiRD
cycles, (range)
7 (4-23) 7 (2-27)
Total lenalidomide dose
delivery, (range)*
7 (4-23) 7.5 (2-27)
Cy indicates cyclophosphamide; G-CSF, granulocyte-colony stimu-
lating factor; SD, standard deviation.
*The relative lenalidomide dose intensity for each patient was calcu-
lated as the ratio of the dose of lenalidomide received (accounting for
dose reductions) to the starting dose of lenalidomide in the BiRD
regimen multiplied by the number of BiRD cycles prior to stem
cell collection.
Stem Cell Collection following Lenalidomide Therapy 797harvests; P 5 .91) or with the absolute number of
CD341 stem cells collected (Spearman rank correlation
coefficient 0.20;P5 .31). Similarly, the absolute dose of
lenalidomide received prior to mobilization was not
significantly associated with success of collection (me-
dian total lenalidomide dose delivery of 7.5 [range 7-
23] for unsuccessful harvests versus 7 [range: 2-27] for
successful harvests; P5 .30). Of note, only 1 patient in
this study had a dose reduction in lenalidomide during
BiRD therapy prior to mobilization, from 25 mg/day
to 10 mg/day for days 1-21 of a 28-day cycle. This
patient was in the group mobilized with G-CSF alone,
and failed adequate stem cell collection.
DISCUSSION
ASCT is a powerful therapeutic option for MM
that has been shown to prolong overall survival (OS)
[12]. In addition, tandem transplants have become an
option for certain patients [4,5], and robust stem cell
collections are now required. Consequently, any in-
duction therapy used to reduce tumor burden prior
to ASCT must not hinder stem cell mobilization and
harvesting for double transplants.
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Figure 1. The number of CD341 cells collected per treatment
group.
Table 2. Stem Cell Mobilization with Granulocyte-Colony Stimulating
Factor (G-CSF) Alone versus Cyclophosphamide (Cy) Plus G-CSF
following BiRD (Biaxin [Clarithromycin]/Revlimid [Lenalidomide]/
Dexamethasone) Therapy
G-CSF
(n 5 9)
Cy plus
G-CSF (n 5 20) P
CD341 collection, 106/kg
Mean (SD) 3.8 (3.3) 32.3 (51.1)
Median (range) 3.1 (0.2-8.6) 14.2 (4.9-236.3) \.0001*
Successful yield,
n (%)
3 (33) 20 (100) \.0001†
SD indicates standard deviation.
*Mann-Whitney U-test.
†Fisher’s exact test.Although Cy and G-CSF have been used for
successful stem cell mobilization [13], this combina-
tion has not been shown to increase response to, or
improve, overall outcomes after ASCT [14].
Furthermore, Desikan and colleagues [15] have
shown that G-CSF alone mobilized adequate
CD341 stem cells more rapidly and with less mor-
bidity in patients with MM than the combination of
Cy plus G-CSF. Yet, these studies were conducted
in patients without exposure to lenalidomide.
More than 6 cycles of lenalidomide-based induction
therapy has been shown to inhibit collection of
CD341 cells for ASCT using mobilization with
G-CSF alone [1], and our study is germane to the
increasing incorporation of this drug into modern
MM treatment. The rationale for inclusion of Cy
as part of a myeloma mobilization regimen in a pa-
tient with prior lenalidomide treatment should be
to increase stem cell yield to allow ASCT, and
also to potentially minimize resource wastage by
decreasing the number of apheresis sessions and
failed collections overall. All the patients mobilized
with Cy plus G-CSF in this study collected suffi-
cient CD341 cells for 2 transplants compared
with 33% of those mobilized with G-CSF alone,
providing a strong argument for the inclusion of
Cy for stem cell mobilization after treatment with
the BiRD regimen. We show that there was no
association of duration of BiRD therapy, or the
total lenalidomide dose received, with successful
CD341 cell collection, and thus, the number of
lenalidomide-based therapy cycles should not be
a limiting factor in stem collection. This a striking
contrast to the experiences reported by Paripati
et al. [10] and Kumar et al. [1] and suggests the
role the Cy may play in mobilizing stem cells
even after prolonged exposure to lenalidomide
therapy. All 3 successful collections in the G-CSF
alone group were in patients treated with\6 cycles
of BiRD; therefore, patients who receive shorter le-
nalidomide courses may collect adequate CD341
cells without the addition of Cy.
The use of clarithromycin caused no bone marrow
toxicity in theBiRDregimen, andwe therefore hypoth-
esize that the use of clarithromycin had no effect on the
stem cell collection outcomes we observed [8,16]. This
report validates theMayo Clinic experience of the sup-
pressive effect of lenalidomide on stem cell mobiliza-
tion, as well as the success achieved using G-CSF plus
Cy for stem cell collection after lenalidomide therapy
[1,17,18]. In conclusion, we recommend continuing le-
nalidomide-based induction therapy until the desired
tumor reduction goal has been achieved, and using
Cy plus G-CSF for stem cell mobilization to ensure
successful stem cell harvest prior to ASCT.This would
particularly apply to those patients who have been
treated with lenalidomide for longer than 6 months.
798 T. Mark et al.ACKNOWLEDGMENTS
This work was supported in part by a SCOR grant
from The Leukemia & Lymphoma Society and an
NCI K23 Award: CA109260-01. Research funds
were also provided by Celgene Corporation. The au-
thors also acknowledge the support of the Hermione
foundation. In preparation of this manuscript, the au-
thors received editorial/writing support from Excerpta
Medica, which was funded by Celgene Corporation.
The authors, however, were fully responsible for con-
tents and editorial decisions for this manuscript.
REFERENCES
1. Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalido-
mide therapy on stem cell mobilization and engraftment post-
peripheral blood stem cell transplantation in patients with newly
diagnosed myeloma. Leukemia. 2007;21:2035-2042.
2. Koreth J, Cutler CS, Djulbegovic B, et al. High-dose therapy
with single autologous transplantation versus chemotherapy for
newly diagnosed multiple myeloma: a systematic review and
meta-analysis of randomized controlled trials. Biol Blood Marrow
Transplant. 2007;13:183-196.
3. Anderson KC, Vesole DH. Stem cell transplant for first relapse
from the multiple myeloma research foundation. Oncology
(Williston Park). 2006;20:1818. 1820–1821, 1825-1826.
4. Attal M, Harousseau JL, Facon T, et al. Single versus double
autologous stem-cell transplantation for multiple myeloma.
N Engl J Med. 2003;349:2495-2502.
5. Barlogie B, Tricot GJ, van Rhee F, et al. Long-term outcome
results of the first tandem autotransplant trial for multiple mye-
loma. Br J Haematol. 2006;135:158-164.
6. Weber DM, Chen C, Niesvizky R, et al., Multiple Myeloma
(009) Study Investigators. Lenalidomide plus dexamethasone
for relapsed multiple myeloma in North America. N Engl J
Med. 2007;357:2133-2142.
7. Dimopoulos M, Spencer A, Attal M, et al., Multiple Myeloma
(010) Study Investigators. Lenalidomide plus dexamethasone
for relapsed or refractory multiple myeloma. N Engl J Med.
2007;357:2123-2132.
8. NiesvizkyR, JayabalanDS,Christos PJ, et al. BiRD (Biaxin [clar-
ithromycin]/Revlimid [lenalidomide]/dexamethasone) combina-
tion therapy results in high complete- and overall-response ratesin treatment-naive symptomatic multiple myeloma. Blood. 2008;
111:1101-1109.
9. Mazumder A, Kaufmann J, Niesvizky R, Lonial S, Vesole D,
Jagannath S. Effect of lenalidomide therapy on mobilization
of peripheral blood stem cells in previously untreated multi-
ple myeloma patients. Leukemia. 2007. Nov 22 [Epub ahead
of print].
10. Paripati H, Stewart AK, Cabou S, et al. Compromised stem cell
mobilization following induction therapy with lenalidomide in
myeloma. Leukemia. 2008. Jan 24 [Epub ahead of print].
11. Durie BG, Harousseau JL, Miguel JS, et al. International Mye-
loma Working Group. International uniform response criteria
for multiple myeloma. Leukemia. 2006;20:1467-1473.
12. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, ran-
domized trial of autologous bone marrow transplantation and
chemotherapy in multiple myeloma. Intergroupe Francais du
Myelome. N Engl J Med. 1996;335:91-97.
13. AbdelkefiA, Ladeb S, TorjmanL, et al. on behalf of theTunisian
Multiple Myeloma Study Group. Single autologous stem-cell
transplantation followed by maintenance therapy with thalido-
mide is superior to double autologous transplantation inmultiple
myeloma: results of amulticenter randomized clinical trial.Blood.
2008;111:1805-1810.
14. Dingli D, Nowakowski GS, Dispenzieri A, et al. Cyclophospha-
midemobilizationdoes not improve outcome inpatients receiving
stem cell transplantation for multiple myeloma. Clin Lymphoma
Myeloma. 2006;6:384-388.
15. Desikan KR, Barlogie B, Jagannath S, et al. Comparable engraft-
mentkinetics followingperipheral-blood stem-cell infusionmobi-
lized with granulocyte colony-stimulating factor with or without
cyclophosphamide in multiple myeloma. J Clin Oncol. 1998;16:
1547-1553.
16. Niesvizky R, Naib T, Christos PJ, et al. Lenalidomide-induced
myelosuppression is associated with renal dysfunction: adverse
events evaluation of treatment-naı¨ve patients undergoing front-
line lenalidomide and dexamethasone therapy. Br J Haematol.
2007;138:640-643.
17. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination ther-
apy with lenalidomide plus dexamethasone (Rev/Dex) for newly
diagnosed myeloma. Blood. 2005;106:4050-4053.
18. Lacy MQ, Gertz MA, Dispenzieri A, et al. Long-term results of
response to therapy, time to progression, and survival with lena-
lidomide plus dexamethasone in newly diagnosed myeloma.
Mayo Clin Proc. 2007;82:1179-1184.
